We are live on ! Find out more
AKYA

Akoya BioSciences

Delisted

AKYA was delisted on the 7th of July, 2025.

73 hedge funds and large institutions have $119M invested in Akoya BioSciences in 2023 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 13 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 13

111% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 9

16% more funds holding

Funds holding: 6373 (+10)

9% more capital invested

Capital invested by funds: $109M → $119M (+$9.61M)

0.74% less ownership

Funds ownership: 34.84%34.1% (-0.74%)

24% less call options, than puts

Call options by funds: $176K | Put options by funds: $232K

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
73
Holders Change
+10
Holders Change %
+15.87%
% of All Funds
1.15%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
19
Increased
31
Reduced
13
Closed
9
Calls
$176K
Puts
$232K
Net Calls
-$56K
Net Calls Change
-$230K
Name Holding Trade Value Shares
Change
Change in
Stake
UBS Group
51
UBS Group
Switzerland
$69.8K +$35.3K +5,286 +127%
AIG
52
American International Group
New York
$64.7K +$7.64K +1,145 +15%
Deutsche Bank
53
Deutsche Bank
Germany
$59.3K -$16.1K -2,408 -23%
Wells Fargo
54
Wells Fargo
California
$56.5K +$27.9K +4,175 +120%
California State Teachers Retirement System (CalSTRS)
55
California State Teachers Retirement System (CalSTRS)
California
$44.7K +$1.25K +188 +3%
Allspring Global Investments
56
Allspring Global Investments
North Carolina
$44.3K -$754K -112,954 -95%
Bank of America
57
Bank of America
North Carolina
$43.9K -$4.39K -657 -10%
Citigroup
58
Citigroup
New York
$40K +$36.2K +5,416 New
Barclays
59
Barclays
United Kingdom
$26.7K -$29.1K -4,364 -55%
AB
60
Amalgamated Bank
New York
$19K +$3.15K +472 +23%
Legal & General Group
61
Legal & General Group
United Kingdom
$14.9K
SIA
62
Sit Investment Associates
Minnesota
$14K
Royal Bank of Canada
63
Royal Bank of Canada
Ontario, Canada
$10K +$1.44K +216 +18%
Simplex Trading
64
Simplex Trading
Illinois
$9K +$8.9K +1,333 New
AIP
65
Ameritas Investment Partners
Nebraska
$8.86K
MLICM
66
Metropolitan Life Insurance Company (MetLife)
New York
$8.61K
Fidelity Investments
67
Fidelity Investments
Massachusetts
$6.02K -$521K -78,019 -99%
TRCT
68
Tower Research Capital (TRC)
New York
$4.09K -$4.6K -689 -55%
ACM
69
Aquatic Capital Management
Illinois
$3K +$2.67K +400 New
LC
70
Lindbrook Capital
California
$1.6K +$1.45K +217 New
Osaic Holdings
71
Osaic Holdings
Arizona
$1.4K
SO
72
STRS Ohio
Ohio
$1K -$10.7K -1,600 -89%
OP
73
ORG Partners
Indiana
$693 +$668 +100 New
HEC
74
Hudson Executive Capital
New York
-$14.2M -1,736,017 Closed
ACM
75
Altium Capital Management
New York
-$4.09M -500,000 Closed

AKYA Hedge Fund Activity: Q2 2023 in Review

73 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Akoya BioSciences (AKYA) for Q2 2023, worth a combined $119M — up 8.8% from $109M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new AKYA positions and 9 closed out — a net gain of 10 holders — while 31 added to existing stakes and 13 trimmed.

The largest buyer was Blue Water Life Science Advisors, adding an estimated $17.4M. The largest seller was Hudson Executive Capital, exiting entirely with an estimated $14.2M sold.

  • 73 institutional investors held Akoya BioSciences (AKYA) as of Q2 2023, up from 63 in Q1 2023.
  • Funds reported $119M of Akoya BioSciences stock for Q2 2023, up 8.8% quarter-over-quarter.
  • 19 funds opened new Akoya BioSciences positions in Q2 2023 and 9 closed out, a net change of +10 holders.
  • The largest Akoya BioSciences buyer in Q2 2023 was Blue Water Life Science Advisors, an estimated $17.4M added.
  • The largest Akoya BioSciences seller in Q2 2023 was Hudson Executive Capital, an estimated $14.2M sold.

Based on aggregated 13F filings for Q2 2023.